Evotec SE share price today

Evotec SE's share price was $1.57 at the close on 4 November 2026. That is 36.9% below its average price over the last 200 trading days. In the last 52 weeks it traded between $1 and $4, and at that close it sat 8% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 21 weeks running.

Over the last 1 year the share price moved −61% while the S&P 500 moved +23%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 12 June 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Evotec SE pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Evotec SE is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Evotec SE posted a net loss of $46.6 M in the Jun 2026 quarter. The full FY25 year was a loss of $104 M. That loss is 32.5% of the quarter's revenue. The same quarter a year earlier lost $43.5 M. 11 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

Evotec SE reported $143 M of revenue in the Jun 2026 quarter, −16.2% on the same quarter a year earlier. Over 4 years it has grown 6.3% a year on average. The last full year, FY25, came in at $788 M. The last four reported quarters add to $717 M.

Revenue is everything the company billed its customers in the period.

FY25 revenue was $788 M, −1.1% on the year before.

Recent pace: the last four quarters grew −8.7% on average, against 6.3% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −7.7%, against −4.6% a year over the last 8 quarters (rolling over).

Evotec SE's operating margin was −62.3% in the Jun 2026 quarter, 42.7 percentage points lower than the same quarter a year ago. Across 5 years it has been between −9.9% and 6.3%. The latest quarter is below every full year in that period.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −42.7 percentage points on the year while gross margin changed −11.1 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Evotec SE's cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $9.2 M of cash, against −$104 M of profit. After $72.5 M of spending on assets, free cash was −$81.7 M: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Evotec SE does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $403 M on assets over the last 3 years. Averaged over those years that is 17.1% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $403 M over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Evotec SE has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Evotec SE at 0.7× its FY25 revenue of $788 M. The P/E comes back here once profit turns positive.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Evotec SE's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Evotec SE earned a ROE of −13% in FY25. That is up from a low of −21% in FY24. Its return on capital used (ROIC) is 27.9 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses.

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

It comes from a −13.1% net margin and 0.46× asset turnover (sales divided by assets).

Why the return is what it is (FY25): a −13.1% net margin × 0.46× asset turnover × 2.11× leverage (assets divided by equity) ≈ −12.7% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: −22.1% − 5.8% = −27.9 percentage points. The 5.8% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

The −22.1% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at −7.4%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Evotec SE has total debt of $476 M against shareholder equity of $666 M as of Jun 2026, so its debt is 0.71× its equity. Year by year, that ratio went from 0.37 in FY21 to 0.55 in FY25. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

We have no ownership or short-position figures for Evotec SE, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 0.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

For Evotec SE, the Z-score is 0.30. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 0.30 is inside the danger zone, so the balance sheet is a real risk.

There is no score against its industry: Evotec SE is not among the largest members shown in this industry comparison for Drug Manufacturers - Specialty & Generic.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

Evotec SE is the 37th largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Esperion Therapeutics, Inc., Collegium Pharmaceutical, Inc. and Ironwood Pharmaceuticals, Inc. Just below it: Evolus, Inc., Aquestive Therapeutics, Inc. and Alpha Teknova, Inc.

Drug Manufacturers - Specialty & Generic companies close in size

34. Esperion Therapeutics, Inc. $819 million
35. Collegium Pharmaceutical, Inc. $771 million
36. Ironwood Pharmaceuticals, Inc. $623 million
37. Evotec SE $576 million
38. Evolus, Inc. $493 million
39. Aquestive Therapeutics, Inc. $478 million
40. Alpha Teknova, Inc. $455 million

All 51 Drug Manufacturers - Specialty & Generic companies, largest first

Companies close in size in other industries

2774. Myriad Genetics, Inc. $576 million · Diagnostics & Research
2775. Vinci Compass Investments Ltd. $576 million · Asset Management
2776. Evotec SE $576 million
2777. Shenandoah Telecommunications Company $575 million · Telecom Services
2778. FrontView REIT, Inc. $573 million · REIT - Diversified

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.